Abbott Laboratories (NYSE:ABT) is one of the Best Bargain Stocks to Buy in June. On June 12, BofA analyst Travis Steed reduced the firm’s price objective on the company’s stock to $102 from $120 and maintained a “Buy” rating on the shares. The analyst took a more conservative view on 2027 med-tech company estimates. This is because the valuations continue to reflect utilization risk, added the analyst. Furthermore, inflation is more of a headwind in 2027, with less margin expansion for medtech.
As a result, the analyst reduced the 2027 estimates throughout the firm’s larger-cap coverage basket where there is exposure to the utilization and inflation.
In a separate release, Abbott Laboratories (NYSE:ABT) announced that it secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people suffering from diabetes. Branded as Libre Duo and Libre Duo 10 Day, such systems tend to continuously measure glucose and ketone levels every minute. This offers real-time visibility into glucose levels required for daily diabetes management and rising ketones that can result in diabetic ketoacidosis (DKA) emergency.
Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.
While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.